Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963609 | 0.81 | PTPN1 (0.56) | NPC1RAB9ASMN1; SMN2DYRK1APTPN1 | |
| SCHEMBL3054828 | 0.79 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2DYRK1AFSCN1 | |
| SCHEMBL11549742 | 0.78 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2DYRK1ACYP1A2 | |
| SCHEMBL11258414 | 0.76 | CASP2 (0.64) | NPC1RAB9ASMN1; SMN2DYRK1AFSCN1 | |
| SCHEMBL11254514 | 0.75 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2DYRK1APIK3CG | |
| SCHEMBL4501407 | 0.74 | DYRK1A (0.71) | NPC1RAB9ASMN1; SMN2DYRK1APIK3CG | |
| SCHEMBL4488488 | 0.74 | HDAC6 (0.50) | NPC1RAB9ASMN1; SMN2DYRK1A | |
| SCHEMBL4496509 | 0.73 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2PIK3CG | |
| SCHEMBL11254531 | 0.72 | MAPK1 (0.49) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11258673 | 0.72 | RAB9A (0.51) | NPC1RAB9ASMN1; SMN2DYRK1APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032583-B1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2007144370-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258857-A1 | CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | NPC1 93/4885RAB9A 696/4885SMN1; SMN2 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.